An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.

MLA

Shafat, Tali, et al. “An International Multicenter Study Comparing COVID‐19 Omicron Outcomes in Patients with Hematological Malignancies Treated with Obinutuzumab versus Rituximab.” Cancer Medicine, vol. 13, no. 3, Feb. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1002/cam4.6997.

APA

Shafat, T., Grupel, D., Porges, T., Abuhasira, R., Belkin, A., Deri, O., Oster, Y., Zahran, S., Horwitz, E., Horowitz, N. A., Khatib, H., Batista, M. V., Cortez, A. C., Brosh, N. T., Segman, Y., Ishay, L., Cohen, R., Atamna, A., Spallone, A., & Chemaly, R. F. (2024). An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab. Cancer Medicine, 13(3), 1–11. https://doi.org/10.1002/cam4.6997

Chicago

Shafat, Tali, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, et al. 2024. “An International Multicenter Study Comparing COVID‐19 Omicron Outcomes in Patients with Hematological Malignancies Treated with Obinutuzumab versus Rituximab.” Cancer Medicine 13 (3): 1–11. doi:10.1002/cam4.6997.